Y
Yuqi Xie
Researcher at Guangzhou Medical University
Publications - 7
Citations - 1363
Yuqi Xie is an academic researcher from Guangzhou Medical University. The author has contributed to research in topics: Medicine & Proinflammatory cytokine. The author has an hindex of 3, co-authored 5 publications receiving 850 citations.
Papers
More filters
Journal ArticleDOI
Modified SEIR and AI prediction of the epidemics trend of COVID-19 in China under public health interventions
Zifeng Yang,Zifeng Yang,Zhiqi Zeng,Ke Wang,Sook San Wong,Sook San Wong,Wenhua Liang,Mark Zanin,Mark Zanin,Liu Peng,Xudong Cao,Zhongqiang Gao,Zhitong Mai,Jingyi Liang,Xiaoqing Liu,Shiyue Li,Yimin Li,Feng Ye,Wei-jie Guan,Yifan Yang,Fei Li,Shengmei Luo,Yuqi Xie,Bin Liu,Zhoulang Wang,Shaobo Zhang,Yaonan Wang,Nanshan Zhong,Jianxing He +28 more
TL;DR: The implementation of control measures on January 23 2020 was indispensable in reducing the eventual COVID-19 epidemic size, and the dynamic SEIR model, trained on the 2003 SARS data, was effective in predicting the epidemic peaks and sizes.
Journal ArticleDOI
Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway.
Qinhai Ma,Weiqi Pan,Run-Feng Li,Bin Liu,Chufang Li,Yuqi Xie,Zhoulang Wang,Jin Zhao,Haiming Jiang,Jicheng Huang,Yongxia Shi,Jun Dai,Kui Zheng,Xiaobo Li,Zifeng Yang +14 more
TL;DR: Findings indicate that LS could inhibit SARS-CoV-2 virus infection via downregulating the expression of inflammatory cytokines induced virus and regulating the activity of NF-κB/MAPK signaling pathway in vitro, making its promising candidate treatment for controlling COVID-19 disease.
Journal ArticleDOI
Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway.
Qinhai Ma,Runfeng Li,Weiqi Pan,Wenbo Huang,Bin Liu,Yuqi Xie,Zhoulang Wang,Chufang Li,Haiming Jiang,Jicheng Huang,Yongxia Shi,Jun Dai,Kui Zheng,Xiaobo Li,Min Hui,Li Fu,Zifeng Yang,Zifeng Yang +17 more
TL;DR: Investigation of the antiviral and anti-inflammatory activities of KD-1 against the novel SARS-CoV-2 and H coV-229E indicated that KD- 1 protected against virus and can thus be used as a novel strategy for controlling coronavirus 2019.
Journal ArticleDOI
Efficacy and safety of ReDuNing injection as a treatment for COVID-19 and its inhibitory effect against SARS-CoV-2.
Qinhai Ma,Yuqi Xie,Zhoulang Wang,Biao Lei,Ruihan Chen,Bin Liu,Haiming Jiang,Yutao Wang,Qingquan Liu,Zifeng Yang +9 more
TL;DR: In this paper, the clinical efficacy of ReDuNing injection in patients with COVID-19 and its antiviral activity against SARS-CoV-2 in vitro was evaluated.
Journal ArticleDOI
Lianhuaqingwen capsule inhibits influenza-induced bacterial adhesion to respiratory epithelial cells through down-regulation of cell adhesion molecules
Qiuling Du,Wenbo Huang,Jin Zhao,Jun Zeng,Wenjie Zhang,Xiaodong Huang,Ruifeng Chen,Haiming Jiang,Yuqi Xie,Yutao Wang,Nanshan Zhong,Xinhua Wang,Zifeng Yang +12 more
TL;DR: Wang et al. as discussed by the authors evaluated the efficacy and underlying mechanism of Lianhuaqingwen capsule (LHQW) on influenza A virus A/PR/8/34 (PR8) secondary methicillin-resistant Staphy-lococcus aureus (MRSA) infection.